Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 8 Carcinoid Tumor 3 Acromegaly 3 Pituitary Neoplasms 2 Neoplasm Metastasis 2 Gastro-enteropancreatic neuroendocrine tumor 2 Carcinoma, Hepatocellular 2 Pheochromocytoma 1 Paraganglioma 1 Neoplastic Cells, Circulating 1 Neoplasms 1 Growth Hormone-Secreting Pituitary Adenoma 1 Gigantism 1 Gastrointestinal Neoplasms 1 Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 12 Radiotherapy 9 avelumab 8 Nivolumab 8 cemiplimab 4 Radiation 4 Ipilimumab 4 poly ICLC 3 atezolizumab 3 Specimen Handling 3 Magnetic Resonance Spectroscopy 3 Etoposide 3 Cyclophosphamide 3 talimogene laherparepvec 2 lutetium Lu 177 dotatate 2 fludarabine phosphate 2 fludarabine 2 durvalumab 2 aldesleukin 2 Interferon-beta 2 Immunoglobulin G 2 Immune Checkpoint Inhibitors 2 Cisplatin 2 Carboplatin 2 Biopsy 2 veliparib 1 vatalanib 1 tremelimumab 1 tocilizumab 1 temsirolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Merkel Cell × lanreotide × Clear all

NCT02351128 2017-10-18

PHRC-Merkel

University Hospital, Grenoble

Phase 2 Completed

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡